Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now
Key takeaways
- PFE ^GSPC NVDA Pfizer (NYSE: PFE) is offering dividend investors a huge 6.9% yield.
- However, that lofty yield is also a sign that this pharmaceutical company is deeply out of favor on Wall Street.
- In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia.
PFE ^GSPC NVDA Pfizer (NYSE: PFE) is offering dividend investors a huge 6.9% yield. To put that into perspective, the S&P 500 index (SNPINDEX: ^GSPC) has a tiny 1% yield right now, and the average pharmaceutical stock's yield is 1.6%. Dividend lovers will clearly find Pfizer's yield attractive.
However, that lofty yield is also a sign that this pharmaceutical company is deeply out of favor on Wall Street. If you have a long-term investment approach that allows you to practice what I call time arbitrage, you may want to consider buying this high-yield drugmaker.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »